UNH

Zacks Research Daily presents hand-picked analysis of 12 major stocks. UnitedHealth Group receives a Neutral rating despite strong Q3 earnings, citing regulatory scrutiny and premium valuation.

ServiceNow faces software competition but benefits from AI adoption and enterprise digitization. 3M outperforms its industry with strong Safety and Industrial momentum, though consumer discretionary weakness persists. Additional coverage includes Otis, Brown & Brown, Ensign Group, Glaukos, Domino's, CarMax, Par Pacific, MP Materials, and Lennar.

UnitedHealth Group reported Q3 adjusted earnings of $4.69 per share, beating estimates by 13.9% with a 60.6% year-over-year increase. The company raised its 2026 EPS outlook to at least $20.50, driven by improved margins and lower medical costs.

However, membership declined to 48.3 million from 50.1 million, raising questions about long-term sustainability. Optum also showed strong recovery with margins expanding to 5.6%. The stock carries a Zacks Rank #2 (Buy) rating with valuation below historical medians.

BWX Technologies, Johnson & Johnson, and UnitedHealth Group have all raised their FY26 outlooks following solid quarterly earnings. BWX Technologies saw strong commercial nuclear operations growth, J&J benefited from pharmaceutical portfolio strength, and UnitedHealth Group showed improving cost trends with a lower medical care ratio.

With September CPI rising 3.7% year-over-year and inflation concerns potentially triggering additional Fed rate hikes, the article recommends three low-beta defensive healthcare stocks: Cardinal Health (CAH), UnitedHealth Group (UNH), and Corcept Therapeutics (CORT). These stocks offer lower market volatility and strong earnings growth prospects in an uncertain economic environment.

UnitedHealth Group is prioritizing Chronic Special Needs Plans (C-SNPs) and Dual Eligible Special Needs Plans (D-SNPs) for 2027 to drive targeted Medicare Advantage growth. UNH expects Medicare margins near the upper end of its 2%-4% target in 2026, with at least 69% of its Medicare Advantage members in four-star or higher rated plans. The company faces competition from Humana and Centene, which are also expanding specialized Medicare Advantage offerings.

UnitedHealth Group raised its 2026 adjusted EPS guidance to at least $20.50 and signaled a return to sustainable earnings growth in 2027. The company reported strong Q3 results with adjusted earnings of $4.69 per share exceeding expectations. While commercial medical costs remain elevated and Medicaid funding gaps persist, Optum Health's earnings rebound and AI expansion initiatives support the recovery outlook.

UnitedHealth Group (UNH) has been identified as a top-ranked momentum stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company received upward earnings estimate revisions, with the consensus estimate increasing to $19.85 per share for fiscal 2026, and has demonstrated a strong average earnings surprise of +14%. The stock is recommended for momentum investors seeking exposure to the healthcare sector.

UnitedHealth Group (UNH) reported Q3 2026 adjusted EPS of $4.69, beating estimates by 13.8% with a 60.6% year-over-year increase. The company improved its medical care ratio to 88.4% and raised its 2026 adjusted EPS guidance to at least $20.50. Strong performance from Optum Insight and Optum Rx offset weakness in Optum Health and declining memberships.

UnitedHealth Group reported Q3 2026 earnings of $4.69 per share, beating consensus estimates of $4.12 and representing a 13.84% surprise. The company posted revenues of $112.69 billion, slightly exceeding expectations.

With a Zacks Rank #2 (Buy) rating, UnitedHealth has outperformed the S&P 500 by 0.6% year-to-date. However, the Medical - HMOs industry ranks in the bottom 24% of Zacks industries, which could impact future performance.

UnitedHealth Group closed at $378.81, up 2.12% and outperforming the S&P 500's 0.6% gain. Despite a 4.46% loss over the past month, the company holds a Zacks Rank #2 (Buy) rating.

UNH is expected to report Q3 earnings on October 13, 2026, with projected EPS of $4.12 (41.1% growth YoY) and revenue of $111.38 billion (down 1.57% YoY). The stock trades at a Forward P/E of 18.69, below the industry average of 20.83.

UnitedHealth Group (UNH) and Humana (HUM) are compared as major players in U.S. managed healthcare. UNH benefits from its diversified Optum platform, improving Medicare Advantage profitability, and $1.5B AI investments, while HUM shows strong Medicare Advantage membership growth of 23.8% but faces margin pressures from rising benefit costs. UNH is rated as the more compelling investment with a Zacks Rank #2 (Buy) versus HUM's Rank #3 (Hold), offering 28.1% upside potential compared to HUM's 7.7%.

UnitedHealth Group closed down 1.42% on October 8, 2026, underperforming the S&P 500's 0.47% loss. The stock has declined 4.35% over the past month.

Upcoming earnings on October 13 are expected to show 41.1% EPS growth to $4.12, though revenue is projected to decline 1.57% to $111.38 billion. UNH holds a Zacks Rank #2 (Buy) with a Forward P/E of 18.94, trading at a discount to its industry average of 21.09.

UnitedHealth Group is expected to report Q3 2026 earnings on October 13, 2026, with projected EPS growth of 41.1% to $4.12 per share, despite a 1.6% revenue decline to $111.38 billion. The company faces headwinds from declining memberships across commercial, Medicare Advantage, and Medicaid segments, but improved medical cost management and operational restructuring are expected to support margin expansion. UnitedHealth trades below its historical valuation median at 17.15X forward earnings, positioning it for potential recovery.

UnitedHealth Group (UNH) has attracted investor attention despite a -4.4% return over the past month. The company is expected to report 41.1% earnings growth for the current quarter and 21.4% for the fiscal year, with a Zacks Rank #2 (Buy) rating. UnitedHealth trades at a discount to peers with a Value Style Score of A, though revenue growth remains modest at -0.2% for the current fiscal year.

UnitedHealth Group heads into Q3 earnings with focus on whether its Q2 medical cost improvements can be sustained. The company improved its medical cost ratio to 86.7% in Q2, though $860 million in favorable reserve development aided results. Key questions include whether underlying medical costs remain stable and whether UnitedHealth can improve Medicare Advantage margins while managing expected membership losses of roughly 1.1 million members in 2025.

Zacks Premium offers investment tools including the Zacks Rank and Style Scores to help investors identify high-performing stocks. The Zacks Rank #1 (Strong Buy) stocks have averaged +23.86% annual returns since 1988, outperforming the S&P 500.

Style Scores rate stocks on value, growth, and momentum characteristics to help investors select stocks with the best chance of outperformance over 30 days. UnitedHealth Group is highlighted as a #2 (Buy) stock with strong Style Scores.

UnitedHealth Group will report Q3 earnings on October 13. The key metric to watch is the medical care ratio (MCR), which measures the percentage of insurance premiums paid out for claims.

A lower MCR improves profitability. UnitedHealth successfully reduced its MCR to 86.7% in Q2 from 89.4% a year earlier, driven by benefit design, pricing discipline, and member mix adjustments. Investors will closely monitor whether the company can maintain or further reduce this critical ratio.

UnitedHealth Group closed at $371.90, up 1.83% and outperforming the S&P 500's 0.73% gain. The stock is rated Zacks Rank #2 (Buy) with an upcoming earnings report on October 13, 2026, expected to show 41.1% EPS growth. UNH trades at a Forward P/E of 18.4, below the industry average of 21.25, and is positioned in the top 9% of industries.

Zacks Equity Research analysts published featured research reports on four stocks. UnitedHealth received a Neutral rating despite strong Q3 earnings and diversified operations, citing regulatory scrutiny and premium valuation concerns.

ServiceNow faces software competition and AI spending risks but benefits from enterprise digitization trends. 3M outperformed its industry with strong momentum in Safety and Industrial segments, though retail weakness and high debt remain concerns. Coffee Holding, a microcap, showed growth potential from acquisitions and improved profitability, but faces commodity price volatility and sustainability concerns.

UnitedHealth reported Q3 2026 earnings with strong operational momentum driven by AI integration and enterprise reforms. The company reiterated its 13-16% long-term growth target, highlighting AI-enabled workflow improvements, a 30% reduction in prior authorizations, and strong commercial client retention heading into 2027. Q3 revenue reached $113 billion with adjusted EPS of $4.69.